Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs

被引:39
作者
Heimbach, T
Oh, DM
Li, LLY
Rodríguez-Hornedo, N
Garcia, G
Fleisher, D
机构
[1] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[2] Aventis Pharmaceut, Bridgewater, NJ 08807 USA
关键词
induction time; phosphate prodrug; precipitation; TAT-59; supersaturation; enzyme;
D O I
10.1016/S0378-5173(03)00287-4
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Many oral phosphate prodrugs have failed to improve the rate or extent of absorption compared to their insoluble parent drugs. Rapid parent drug generation via intestinal alkaline phosphatase can result in supersaturated solutions, leading to parent drug precipitation. The purpose was to (1) investigate whether parent drugs can precipitate from prodrug solutions in presence of alkaline phosphatase; (2) determine whether induction times are influenced by (a) dephosphorylation rate, (b) parent drug supersaturation level, and (c) parent drug solubility. Induction times were determined from increases in optical densities after enzyme addition to prodrug solutions of TAT-59, fosphenytoin and estramustine phosphate. Apparent supersaturation ratios (a) were calculated from parent drug solubility at intestinal pH. Precipitation could be generated for all three prodrugs. Induction times decreased with increased enzyme activity and supersaturation level and were within gastrointestinal residence times for TAT-59 concentration greater than or equal to 21 muM (sigma greater than or equal to 210). Induction times for fosphenytoin were less than the GI residence time (199 min) for concentrations of approximately 352 muM (sigma = 4.0). At approximately 475 muM (sigma = 5.3) the induction times were less than 90 min. For estramustine-phosphate, no precipitation was observed within GI residence times. Enzyme-mediated precipitation will depend on apparent supersaturation ratios, parent drug dose, solubility and solubilization by the prodrug. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:81 / 92
页数:12
相关论文
共 31 条
[1]
GROWTH AND DISSOLUTION OF ORGANIC-CRYSTALS WITH TAILOR-MADE INHIBITORS - IMPLICATIONS IN STEREOCHEMISTRY AND MATERIALS SCIENCE [J].
ADDADI, L ;
BERKOVITCHYELLIN, Z ;
WEISSBUCH, I ;
VANMIL, J ;
SHIMON, LJW ;
LAHAV, M ;
LEISEROWITZ, L .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1985, 24 (06) :466-485
[2]
AMIDON G L, 1985, Journal of Controlled Release, V2, P13, DOI 10.1016/0168-3659(85)90029-X
[3]
Crison J. R., 2000, WATER INSOLUBLE DRUG, P97
[4]
Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide [J].
deJong, RS ;
Mulder, NH ;
Uges, DRA ;
Kaul, S ;
Winograd, B ;
Sleijfer, DT ;
Groen, HJM ;
Willemse, PHB ;
vanderGraaf, WTA ;
deVries, EGE .
BRITISH JOURNAL OF CANCER, 1997, 75 (11) :1660-1666
[5]
Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs [J].
Fleisher, D ;
Bong, R ;
Stewart, BH .
ADVANCED DRUG DELIVERY REVIEWS, 1996, 19 (02) :115-130
[6]
Influence of supersaturation and structurally related additives on the crystal growth of α-lactose monohydrate [J].
Garnier, S ;
Petit, S ;
Coquerel, G .
JOURNAL OF CRYSTAL GROWTH, 2002, 234 (01) :207-219
[7]
Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation [J].
Gu, CH ;
Young, V ;
Grant, DJW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (11) :1878-1890
[8]
Absorption rate limit considerations for oral phosphate prodrugs [J].
Heimbach, T ;
Oh, DM ;
Li, LY ;
Forsberg, M ;
Savolainen, J ;
Leppänen, J ;
Matsunaga, Y ;
Flynn, G ;
Fleisher, D .
PHARMACEUTICAL RESEARCH, 2003, 20 (06) :848-856
[9]
HEIMBACH T, 2000, AAPS ANN M IND IN US
[10]
HEIMBACH T, 2002, AAPS ANN M TOR CAN